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Open access unda b s t r a c t
The actions of tamoxifen, a selective estrogen receptor modulator used in chemotherapy and chemo-
prevention of breast cancer, on glycolysis and gluconeogenesis were investigated in the isolated perfused
rat liver. Tamoxifen inhibited gluconeogenesis from both lactate and fructose at very low concentrations
(e.g., 5 lM). The opposite, i.e., stimulation, was found for glycolysis from both endogenous glycogen and
fructose. Oxygen uptake was unaffected, inhibited or stimulated, depending on the conditions. Stimula-
tion occurred in both microsomes and mitochondria. Tamoxifen did not affect the most important
key-enzymes of gluconeogenesis, namely, phosphoenolpyruvate carboxykinase, pyruvate carboxylase,
fructose 1,6-bisphosphatase and glucose 6-phosphatase. Conﬁrming previous observations, however,
tamoxifen inhibited very strongly NADH- and succinate-oxidase of freeze–thawing disrupted mitochon-
dria. Tamoxifen promoted the release of both lactate dehydrogenase (mainly cytosolic) and fumarase
(mainly mitochondrial) into the perfusate. Tamoxifen (200 lM) clearly diminished the ATP content
and increased the ADP content of livers in the presence of lactate with a diminution of the ATP/ADP ratio
from 1.67 to 0.79. The main causes for gluconeogenesis inhibition are probably: (a) inhibition of energy
metabolism; (b) deviation of intermediates (malate and glucose 6-phosphate) for the production of
NADPH required in hydroxylation and demethylation reactions; (c) deviation of glucosyl units toward
glucuronidation reactions; (d) secondary inhibitory action of nitric oxide,whose production is stimulated
by tamoxifen; (e) impairment of the cellular structure, especially the membrane structure. Stimulation of
glycolysis is probably a compensatory phenomenon for the diminished mitochondrial ATP production.
The multiple actions of tamoxifen at relatively low concentrations can represent a continuous burden
to the overall hepatic functions during long treatment periods.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Tamoxifen (TAM) or trans-1-[p-b-(dimethyl-amino)ethoxy-
phenyl]1,2-diphenyl-1-butene is a substituted trans isomer of
triphenylethylene. It belongs to the class of compounds with anti-
estrogen activity, used in chemotherapy and chemo-prevention of
breast cancer [1,2]. It is classiﬁed as a selective estrogen receptor
modulator because it acts as an estrogen agonist in some tissues
and as an antagonist in others [3].
Due to its lipophilic nature tamoxifen strongly incorporates into
biomembranes and interacts with lipids and proteins [4–6]. The
partition coefﬁcient of tamoxifen between an aqueous medium
and multilamellar dimyristoyl-phosphatidylcholine liposomesase; GAPDH, glyceraldehyde
hate dehydrogenase; G6Pase,
, malate dehydrogenase; NO,
enolpyruvate carboxykinase.
: +55 44 30114896.
er the Elsevier OA license.was reported to be around 3.9  104 [7]. Concerning the membrane
dynamics, it has been recently shown that tamoxifen decreases
membrane ﬂuidity at low concentrations but that the opposite oc-
curs at high concentrations. The precise mechanisms of these ac-
tions of tamoxifen are uncertain [8].
Investigations have also shown that tamoxifen interacts very
strongly with mitochondria isolated from rat liver and mammary
cancer cells. These interactions can inﬂuence the mitochondrial
bioenergetics [9]. Tamoxifen and its metabolite 4-hydroxytamoxi-
fen affect electron ﬂow in the respiratory chain, stimulate ATP
hydrolysis [10] and impair the generation and maintenance of
the electrochemical membrane potential [11]. Incubation of the
mitochondria with increasing concentrations of tamoxifen resulted
in progressive inhibition of oxygen consumption with almost com-
plete inhibition at the concentration of 200 lM. Low concentra-
tions of tamoxifen (15–30 lM) were initially stimulatory and
subsequently inhibitory. Tamoxifen inhibits the electron ﬂow in
the respiratory chain mainly at the complex III (ubiquinone-
cytochrome c reductase) and to a lesser extent at complex IV
(cytochrome c oxidase). The ADP/O ratio is diminished by
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acts as an uncoupler, as already indicated by its negative action
on the membrane potential [11]. At low tamoxifen concentrations,
diminution of the ADP/O ratio is mainly the result of a stimulation
of state IV respiration. At higher concentrations, state III respira-
tion is inhibited. There is a correlation between the stimulation
of state IV respiration and the diminution of the transmembrane
potential in consequence of the increased proton permeability of
the mitochondrial membrane caused by tamoxifen. More recently
it has been shown by experiments with isolated mitochondria that
submicromolar concentrations of tamoxifen stimulate the mito-
chondrial NO synthase activity by elevating the mitochondrial
Ca2+ concentration [12,13]. It has been proposed that these multi-
ple effects of tamoxifen and its metabolites on mitochondrial bio-
energetic functions, causing changes in respiration,
phosphorylation efﬁciency, and membrane structure, may explain
the cell death induced by this drug in different cell types, its sev-
eral side effects and possibly also its anticancer activity in estrogen
receptor-negative cells [10]. Furthermore, it is important to point
out that the actions of tamoxifen and its metabolites on mitochon-
drial bioenergetic functions must have important consequences for
the cellular metabolism in general. In particular, glycolysis is ex-
pected to be stimulated and gluconeogenesis to be inhibited in re-
sponse to changes in the energy status induced by tamoxifen.
These propositions, however, are still hypotheses because no
experimental evidence with intact cell systems has been produced
until now. Filling this gap requires experiments in which the drug
is given to intact cells and metabolic ﬂuxes are measured. This is
precisely the purpose of the present work in which the actions of
tamoxifen on glycogen- and fructose-driven glycolysis and gluco-
neogenesis were investigated using the isolated perfused rat liver.
The results should provide a ﬁrst insight into the action of tamox-
ifen on intact cell systems, providing background information for
its toxicological and physiological side effects.2. Material and methods
2.1. Materials
The liver perfusion apparatus was built in the workshops of the
University of Maringá. Tamoxifen, 4-hydroxytamoxifen and all en-
zymes and coenzymes used in the enzymatic assays were pur-
chased from Sigma Chemical Co. (St. Louis, MO,USA). Sodium
[14C]bicarbonate (speciﬁc activity of 58 Ci/mmol) was purchased
from Amersham Pharmacia Biotech (Buckinghamshire, UK). All
other chemicals were from the best available grade (98–99.8%
purity).
2.2. Animals
Male albino rats (Wistar), weighing 180–220 g, were fed ad libi-
tum with a standard laboratory diet (Nuvilab, Colombo, Brazil). In
most experimental protocols, the rats were starved for 24 h before
the surgical removal of the liver. All experiments were done in
accordance with the internationally accepted recommendations
in the care and use of animals.
2.3. Liver Perfusion and analytics
For the surgical procedure, the rats were anesthetized by intra-
peritoneal injection of thiopental (50 mg/kg). Hemoglobin-free,
nonrecirculating perfusion was performed [14]. After cannulation
of the portal and cava veins, the liver was positioned in a plexiglass
chamber. The perfusion ﬂuid was Krebs/Henseleit-bicarbonate
buffer (pH 7.4), saturated with a mixture of oxygen and carbondioxide (95:5) by means of a membrane oxygenator with simulta-
neous temperature adjustment at 37 C [14,15]. The ﬂow, provided
by a peristaltic pump, was between 30 and 33 mL/min. Due to its
low water solubility (maximally 6.5 lM; [16]), tamoxifen was
added to the perfusion ﬂuid as a dimethylsulfoxide solution to
achieve the desired ﬁnal concentration. Previous to the tamoxifen
or 4-hydroxytamoxifen addition the Krebs/Henseleit-bicarbonate
buffer was supplemented with fatty acid-free bovine serum albu-
min to ensure full dissolution of the drugs. For all concentrations
of the drugs the molar albumin/drug ratio was equal to 2.4. The
solvent dimethylsulfoxide was used solely as the carrier and its
contribution in maintaining the solubility of tamoxifen in the per-
fusion ﬂuid or incubation solutions was negligible as its ﬁnal con-
centration was around 0.02%. Even so, in all cases control
experiments were run in order to exclude unspeciﬁc effects of
dimethylsulfoxide.
The cell viability of the perfused liver was judged from both the
oxygen uptake rates and the perfusion ﬂuid leakage from its sur-
face. The livers were discarded when the oxygen uptake droped
to 0.7 lmol min1 g1 (except in those experiments in which cya-
nide was infused) or when the surface ﬂuid leakage surpassed 2.5%
of the portal ﬂow .
Samples of the efﬂuent perfusion ﬂuid were collected according
to the experimental protocol and analyzed for their metabolite
contents. The following compounds were assayed by means of
standard enzymatic procedures: glucose, lactate and pyruvate
[17]. The oxygen concentration in the outﬂowing perfusate was
monitored continuously, employing a Teﬂon-shielded platinum
electrode adequately positioned in a plexiglass chamber at the exit
of the perfusate [14]. Metabolic rates were calculated from input–
output differences and the total ﬂow rates and were referred to the
wet weight of the liver.
The hepatic contents of adenine nucleotides were measured
after freeze-clamping the perfused liver with liquid nitrogen. The
freeze-clamped livers were extracted with perchloric acid. The ex-
tract was neutralized with K2CO3 and AMP, ADP, and ATP were as-
sayed by means of standard enzymatic procedures [17].
2.4. Assay of enzymatic activities
Two enzymatic activities in the outﬂowing perfusate were
measured: lactate dehydrogenase and fumarase. The lactate dehy-
drogenase activity was measured by following the oxidation of
NADH at 340 nm. The reaction medium contained 80 mM phos-
phate buffer (pH 7.4), 80 lM NADH and 0.6 mM pyruvate [17].
The fumarase activity was measured by following the hydration
of fumarate at 250 nm. The reaction medium contained Krebs-
Henseleit-bicarbonate buffer (pH 7.6) and 1 mM fumarate [17].
In both cases initial rates were evaluated from the recorder trac-
ings and expressed as lmol or nmol minute1 (ml outﬂowing
perfusate)1.
The following enzymes in the liver tissue were assayed for its
sensitivity to tamoxifen: glucose 6-phosphatase, fructose 1,6-bis-
phosphatase, phosphoenol-pyruvate carboxykinase, pyruvate car-
boxylase, succinate oxidase and NADH-oxidase. Glucose 6-
phosphatase was assayed by using a microsomal suspension.
Microsomes were isolated by differential centrifugation [18,19].
Rats were decapitated and their livers excised, cut into small
pieces with scissors and washed with a cold (4 C) aqueous solu-
tion (isolation medium) containing 150 mM KCl, 0.1 mM phen-
ylmethanesulfonyl-ﬂuoride (PMSF) and 10 mM Tris–HCl (pH
7.4). After suspension in 10 volumes of the isolation medium,
the tissue was homogenized with a Dounce homogenizer. The
homogenate was ﬁltered through gauze and centrifuged at
2550g for 10 min in a refrigerated centrifuge. The supernatant
was again centrifuged in two steps of 7100 and 12,400g for
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collected and centrifuged at 105,000g for 1 h. The pellet contain-
ing the microsomal fraction was suspended in cold isolation
medium at a ﬁnal protein concentration of 20 mg protein/mL.
The incubation medium for the glucose 6-phosphate assay con-
tained 100 mM KCl, 5 mM MgCl2, 20 mM Tris–HCl (pH 7.2),
15 mM glucose 6-phosphate, and 0.1–0.2 mg microsomal protein
[20]. After 20 min incubation at 37 C, the reaction was stopped
by the addition of one volume of 5% trichloroacetic acid and
phosphate release was measured [21]. Rates were expressed as
lmol min1 (mg protein)1.
The supernatant of the 105,000g centrifugation obtained during
the microsome isolation procedure was used for the determination
of D-fructose 1,6-bisphosphatase and phosphoenolpyruvate car-
boxykinase (PEPCK) activities [22]. The reaction mixture for the
D-fructose 1,6-bisphosphatase assay contained 0.4–0.8 mg pro-
tein/mL, 100 mM Tris–HCl (pH 8), 12 mM MgCl2, 1 mM D-fructose
1,6-bisphosphate, and 5 mM cysteine. After 20 min incubation at
38 C, the reaction was interrupted by the addition of one volume
of 5% trichloroacetic acid and phosphate release was measured
[21]. Rates were expressed as lmol min1 (mg protein)1. The
phosphoenolpyruvate carboxykinase (PEPCK) activity was assayed
in the direction of oxaloacetate formation, using the malate dehy-
drogenase reaction as the indicator reaction [23]. The assay med-
ium contained 50 mM HEPES buffer (pH 7.0), 100 lM MnCl2,
5 mM MgCl2, 20 mM KHCO3, 2 mM glutathione, 0.2 mM NADH,
2 mM phosphoenolpyruvate, 100 lM GDP and 8.7 units/ml L-ma-
late dehydrogenase. The oxidation of NADH was measured at
340 nm and the enzymatic activity was expressed as lmol min1
(mg protein)1.
The pyruvate carboxylase activity of intact mitochondria was
assayed by measuring the incorporation of 14C from [14C]NaHCO3
into components of the tricarboxylic acid cycle. For mitochondria
isolation, rats were decapitated, their livers removed immediately
and cut into small pieces. The fragments were suspended in a med-
ium containing 0.2 M mannitol, 75 mM sucrose, 2.0 mM Tris–HCl
(pH 7.4), 0.2 mM EGTA, and 50 mg% fatty acid-free bovine-serum
albumin. Homogenization was carried out in the same medium
by means of a van Potter–Elvehjem homogenizer. After homogeni-
zation, the mitochondria were isolated by differential centrifuga-
tion [24] and suspended in the same medium, which was kept at
0–4 C. Protein content of the microsomal and mitochondrial sus-
pensions was measured using the Folin–phenol reagent and bo-
vine-serum albumin as a standard [25]. The incubation medium
contained 5 mM pyruvate, 12.5 mM MgCl2, 2.5 mM potassium
phosphate, 120 mM KCl, 10 mM HEPES (pH 7.5), and 3 mg pro-
tein/mL [26]. The reaction was initiated by introducing 12 mM
[14C]NaHCO3 (0.25 lCi). After 10 min of incubation at 37 C, the
reaction was arrested by the addition of a 0.5 volumes of 2 M per-
chloric acid. After expulsion of the remaining [14C]NaHCO3 (5 min),
aliquots were taken for counting the acid stable incorporated
radioactivity. The incorporated radioactivity was expressed as
nmol min1 (mg protein)1. The scintillation solution for counting
14C was composed of toluene/Triton X-100 (1.5/0.5), 10 g/L 1,5-
diphenyloxazole plus 0.4 g/L of 2,2-p-phenyl-bis-5-
phenyleneoxazole.
Freeze–thawing disrupted mitochondria were used as enzyme
source for assaying the succinate- and NADH-oxidase activities
[27]. Mitochondria were freezed in liquid nitrogen and rapidly
thawed at 37 C. This procedure was repeated three times. The dis-
rupted mitochondria were incubated in the closed chamber of an
oxygraph (0.25 mg protein/ml) in a medium containing 20 mM
Tris–HC1 (pH 7.4) and 1 mM NADH or 5 mM succinate. Oxygen
consumption was monitored polarographically and the rate com-
puted from the slope of the recorder tracings. Rates were expressed
as nmol min1 (mg protein)1.2.5. Treatment of data
The statistical signiﬁcance of the differences between parame-
ters obtained in the experiments was evaluated by means of Stu-
dent’s t test; p < 0.05 was the criterion of signiﬁcance. The
Scientist software from MicroMath Scientiﬁc Software (Salt Lake
City, UT) was used for least-square ﬁttings and for Stineman’s
interpolations.3. Results
3.1. Glycogen catabolism
The ﬁrst experiments were done with subtrate-free perfused
livers from fed rats. These livers survive at the expense of glycogen
degradation via glycolysis and oxidation of endogenous fatty acids
[15]. The parameters that were measured were oxygen consump-
tion, glucose release, lactate production and pyruvate production.
Fig. 1 shows the time courses of experiments in which tamoxifen
was infused at the concentrations of 25 (Fig. 1A) and 200 lM
(Fig. 1B) during a period of 20 min. At the concentration of
25 lM, tamoxifen produced only a small increment in oxygen con-
sumption. All other parameters were not changed. The increment
in oxygen consumption was much more pronounced when the
tamoxifen concentration was raised to 200 lM. At this concentra-
tion also, a clear increase in lactate production was observed. Glu-
cose release experienced some poorly deﬁned oscillations. The
effects were only partially reverted during the 20 min following
cessation of the infusion of tamoxifen. Experiments like those illus-
trated by Fig. 1A and B were repeated with other tamoxifen con-
centrations in the range between 25 and 200 lM and the
changes caused in oxygen uptake and lactate production were rep-
resented against the tamoxifen concentration in Fig. 2A. The graph
shows that the increment of oxygen uptake was not signiﬁcantly
increased in the range between 50 and 200 lM tamoxifen. Lactate
production, however, increased with the concentration of tamoxi-
fen, with an especially pronounced increment in the passage from
100 to 200 lM (71% stimulation relative to the basal rate).
To verify if oxygen uptake stimulation comes from the mito-
chondria, the microsomal electron transport chain or from both,
experiments were done with cyanide which at the concentration
of 1 mM blocks the mitochondrial respiratory chain [15]. Under
these conditions the respiratory rate of the liver was reduced to
0.76 ± 0.04 lmol min1 g1, which corresponds to the activity of
the microsomal electron transport chain plus the loss of oxygen
by diffusion. Under these conditions, 200 lM tamoxifen still in-
creased oxygen consumption by 0.12 ± 0.01 lmol min1 g1. In
the absence of cyanide the increment was equal to
0.31 ± 0.04 lmol min1 g1, meaning thus that the contribution
of the microsomal electron transport chain corresponds to approx-
imately 38%.3.2. Lactate gluconeogenesis
If the increments in lactate production (glycolysis) are conse-
quence of an uncoupling action of tamoxifen, the compound should
equally affect the reversal of glycolysis, namely the transformation
of lactate into glucose. Fig. 1C and D exemplify the time courses of
glucose production from 2 mM lactate in experiments in which
10 lM (Fig. 1C) and 100 lM (Fig. 1D) tamoxifen were infused in liv-
ers of 24-h fasted rats. Before lactate infusion, the rate of glucose re-
leasewasminimal due to the lowendogenous levels of glycogen and
gluconeogenic substrates. Oxygenuptakewashigh because the cells
of substrate-free perfused livers are able to survive at the expense of
endogenous fatty acid oxidation [15]. Both gluconeogenesis and
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Fig. 1. Time courses of the actions of different tamoxifen concentrations on glycogen catabolism (panels A and B) and glucose synthesis (panels C and D) plus associated
parameters in perfused livers. Livers were perfused as described under Materials and Methods with substrate-free perfusion ﬂuid. For investigating glycogen catabolism livers
from fed rats were used; lactate gluconeogenesis was measured in livers from 24-h fasted rats. Tamoxifen (panels A–D) and lactate (panels C–D) were infused at the indicated
times and concentrations. Samples of the efﬂuent perfusate were collected for metabolite assay. Oxygen in the outﬂowing perfusate was monitored polarographically. Data
represent the means ± mean standard errors of three liver perfusion experiments.
C.B. Marek et al. / Chemico-Biological Interactions 193 (2011) 22–33 25oxygen uptake increased progressively upon introduction of lactate,
tending to stabilize at 30 min infusion time. The same occurredwith
pyruvate production. The introduction of tamoxifen at 40 min pro-
duced almost no changes in pyruvate production irrespective of
the concentration. Oxygen uptake was not changed by 10 lMtamoxifen, but oscillations were apparent with 100 lM tamoxifen.
Glucose production, however, suffered a rapid decrease with
100 lM tamoxifen. This decrease slowed down after 6–8 min, but
it was still clearly in progress at 60 min perfusion time. With
10 lM tamoxifen, gluconeogenesis also showed a clear decreasing
50 100 150 200
0
0.2
0.4
0.6
0.8
1.0
0
0.1
0.2
0.3
0.4
0.5
25
Tamoxifen concentration (µM)
 Oxygen
 Lactate
A Glycogen catabolism
ΔL
ac
ta
te
 p
ro
du
ct
io
n
 
(μm
o
l m
in
−
1  
g−
1 ) 
ΔO
xy
ge
n 
co
n
su
m
pt
io
n
 (μ
m
o
l m
in
−
1  
g−
1 ) 
0 50 100 150 200
0
0.2
0.4
0.6
0.8
1.0
1.2
Tamoxifen concentration (µM)
Lactate
Oxygen
B
Δ L
ac
ta
te
 
pr
o
du
ct
io
n
 
o
r 
Δ o
xy
ge
n
 
co
n
su
m
pt
io
n
 
( μm
o
l m
in
−
1
g−
1 ) 
Fructose catabolism
Fig. 2. Concentration dependence of the effects of tamoxifen on oxygen consump-
tion and lactate production in livers from fed rats (panel A) and in livers from fasted
rats during fructose infusion (panel B). Data were obtained from experiments of the
kind illustrated by Fig. 1A,B and 5. Data in panel A (glycogen catabolism) were
computed as the differences between the values found after 20 min tamoxifen
infusion (30 min perfusion time) and the values measured just before initiation of
tamoxifen infusion (10 min perfusion time; Fig. 1B). Data in panel B (fructose
catabolism) represent the maximal increases in lactate production and oxygen
uptake, calculated by subtracting the rate just before starting tamoxifen infusion (at
30 min fructose infusion in Fig. 5) from the peak values during the subsequent
period of tamoxifen infusion. Each datum point represents the mean ± standard
errors from 3 liver perfusion experiments.
26 C.B. Marek et al. / Chemico-Biological Interactions 193 (2011) 22–33trend during the whole infusion time. Fig. 1C and D suggest a negli-
gible effect of tamoxifen on oxygen uptake and pyruvate production
in the presence of lactate, but it also suggests a time dependent inhi-
bitionof glucoseproductioneven at lowconcentrations. For this rea-
son the time dependent action of tamoxifen on lactate
gluconeogenesis was investigated by extending the infusion time,
especially at low concentrations of the drug. The results are shown
in Fig. 3A. Tamoxifen was infused at various concentrations in the
range from 5 to 200 lM. At the lowest concentrations the infusion
was prolonged for 2 h. During such a long time lactate gluconeogen-
esis decreased also in the absence of tamoxifen, as shownby the con-
trol curve n Fig. 3A. However, this decrease was accelerated by
tamoxifen even at the low concentration of 5 lM. Moreover, this
acceleration was clearly dependent on the concentration. The
tamoxifen derivative and metabolite 4-hydroxytamoxifen, as re-
vealedbyFig. 3B, also inhibitedgluconeogenesis. Its action,however,
was considerably faster at low concentrations. Oxygen uptake also
declined with time from 2.64 ± 0.06 lmol min1 g1 at 40 min per-
fusion time to2.18 ± 0.07 lmol min1 g1 at160 minperfusion time
(not shown). This decline, however, was not accelerated by tamoxi-fen. Actually there was a clear tendency toward stimulation during
the ﬁrst 30 min of tamoxifen infusion, especially at the concentra-
tion of 50 lM (data not shown). Pyruvate production, on the
other hand, increased in the control experiments
from 0.40 ± 0.04 lmol min1 g1 at 40 min perfusion time to
0.61 ± 0.05 lmol min1 g1 at 160 min perfusion time. This in-
creased was progressively abolished by tamoxifen, but inhibition
was only apparent at the concentrations of 100 and 200 lM.
Examination of the time-courses in Fig. 3 indicates that the
declines in gluconeogenesis caused by both tamoxifen and
4-hydroxytamoxifen were initially linear functions of time. This al-
lows to use the initial slopes of the declines as indicators for the
inhibitory activity of both tamoxifen and 4-hydroxytamoxifen.
For this purpose the initial declining slopes were evaluated by
means of a least-squares procedure. Their values were represented
in Fig. 4A against the tamoxifen or 4-hydroxytamoxifen concentra-
tions after subtracting the slope measured in the absence of the
drugs. These slopes were expressed as decreases in gluconeogene-
sis per minute (Dgluconeogenesis/minute). They can thus be re-
garded as the rate of gluconeogenesis inhibition caused by each
drug. Fig. 4A reveals that the rate of gluconeogenesis inhibition
by tamoxifen is roughly proportional to its concentration in the
range up to 200 lM. Fig. 4A also shows that 4-hydroxytamoxifen
is much more effective as an inhibitor.
3.3. Fructose metabolism
The time courses of the responses of the perfused liver to
tamoxifen in the presence of fructose are illustrated by Fig. 5A
(25 lM) and B (200 lM). The infusion of fructose usually produces
rapid increases in glucose production, lactate production, pyruvate
production and oxygen uptake [28]. Lactate plus pyruvate produc-
tions are good indicators for the cytosolic ATP production. Tamox-
ifen was active on all parameters of fructose metabolism. Glucose
production was inhibited, slowly by 25 lM and rapidly by 200 lM
tamoxifen. With the latter concentration, inhibition was almost
complete at 90 min perfusion time. Lactate production was in-
creased at low and high tamoxifen concentrations. However, at
high tamoxifen concentrations, this stimulation tended to be re-
versed and transformed into inhibition at longer perfusion times.
Maximal stimulation of lactate production was 54%. Practically
the same can be said about oxygen uptake. Strong inhibition took
place at 90 min perfusion time during the infusion of 200 lM
tamoxifen. The effects on pyruvate production were negligible at
low tamoxifen concentrations (Fig. 5A) but tended to be inhibitory
at high concentrations (Fig. 5B).
Effect versus concentration relationships with respect to the ac-
tions of tamoxifen on fructose metabolism can be seen in Figs. 2
and 4B. Fig. 2B shows the concentration dependence of the stimu-
latory effects on lactate production and oxygen uptake. Peak values
were represented for the tamoxifen concentrations where inhibi-
tion took place at longer infusion times. In all cases stimulation
did not increase when the tamoxifen concentration was raised
above 50 lM. In Fig. 4B the initial declining slopes of glucose pro-
duction, meaning the rates of gluconeogenesis deacceleration,
were represented as a function of the tamoxifen concentrations.
It shows a clear concentration dependence, which is quantitatively
similar to that found when lactate was the substrate (Fig. 4A).
3.4. Adenine nucleotide contents
An action of tamoxifen on mitochondrial energy metabolism
should be detectable in the perfused liver as modiﬁcations in the
ATP levels and ATP/ADP ratios. To investigate this possibility the
tissue levels of AMP, ADP and ATP were measured in the presence
of lactate alone or lactate + 200 lM tamoxifen. The results are
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standard errors of 3–5 liver perfusion experiments.
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and increased the ADP content. As a result, the ATP/ADP ratio, an
important regulatory factor, was substantially decreased, from
1.67 to 0.79. The AMP content was also decreased by tamoxifen
and to such an extent that the ATP/AMP ratio, another important
regulatory factor, was not signiﬁcantly modiﬁed.3.5. Effects on enzymatic activities
The inhibitory action on glucose synthesis could be the conse-
quence of an inhibition of key-enzymes of gluconeogenesis,
namely phosphoenolpyruvate carboxykinase, pyruvate carboxyl-
ase, fructose 1,6-bisphosphatase and glucose 6-phosphatase. For
this reason these enzymes were assayed using the traditional stan-
dardized methods. Fig. 6 reveals that tamoxifen was without any
direct effect on the activities of all those key-enzymes in the range
up to 200 lM. The NADH-oxidase and succinate-oxidase of dis-
rupted mitochondria were also assayed as positive controls. As
shown in Fig. 6, they were highly sensitive to tamoxifen, inhibition
being nearly complete at concentrations below 50 lM. These re-
sults conﬁrm previous observations [10].3.6. Enzyme release
Enzyme losses, which can affect gluconeogenesis [29], are usu-
ally considered as indicators for changes in membrane ﬂuidity,
trafﬁcking and permeability [4–6]. In order to verify this possibility
the release of two enzymes was measured in the present work, lac-
tate dehydrogenase, which is prodominantly cytosolic [30], and
fumarase, predominantly mitochondrial [31]. The results of these
experiments are summarized in Fig. 7. In general it can be said that
tamoxifen promoted the release of both lactate dehydrogenase and
fumarase. When infused at the low concentration of 20 lM (panel
C) the action of tamoxifen presented considerable delay. The re-
lease of both enzymes started at 40–50 min after initiation of
tamoxifen infusion. It increased slowly and reached a plateau after
110 min. At higher concentrations (50–200 lM, panels A and B),
the action of tamoxifen was much faster, with peak values before
or around 30 min after starting the infusion. These peak valuestended to be considerably higher that the late pleateaus that were
reached with the concentration of 20 lM, as revealed by compari-
son of the scales in panels A–B and C.4. Discussion
The present study demonstrates that tamoxifen and at least one
of its metabolites (4-hydroxytamoxifen) are active on liver metab-
olism. Tamoxifen (1) inhibits gluconeogenesis from the two impor-
tant substrates lactate and fructose at low concentrations (e.g.,
5 lM), (2) increases glycolysis, and (3) affects oxygen uptake in a
complex way, inhibition or stimulation depending on the condi-
tions. Due to the structural similarities of the various tamoxifen
metabolites it is likely that several of them can exert the same ef-
fects as tamoxifen itself and 4-hydroxytamoxifen.
At least six reasons can be devised for gluconeogenesis (glucose
output) inhibition: (a) inhibition of mitochondrial functions [9–
12]; (b) deviation of a fraction of glucose 6-phosphate into the pen-
tose-monophosphate shunt for the production of reducing equiva-
lents in the form of NADPH to be used in the tamoxifen stimulated
microsomal electron transport [32]; (c) deviation of cytosolic ma-
late (in equilibrium with oxaloacetate) for the production of
NADPH [32]; (d) deviation of a fraction of glucose 6-phosphate
for glucuronidation reactions [33]; (e) secondary inhibitory action
of nitric oxide [34] whose production is stimulated by tamoxifen
[12]; (f) impairment of the cellular structure, especially the mem-
brane structure [7,8]. For all these points experimental evidence is
available here or elsewhere and they will be discussed in some de-
tail below in the same sequence in which they were mentioned.
Fig. 8 provides graphic illustration of the actions of tamoxifen
which can lead to gluconeogenesis inhibition.
Inhibition of energy metabolism is an expected phenomenon if
one takes into account previous reports. Brieﬂy, tamoxifen and its
metabolite 4-hydroxytamoxifen inhibit electron ﬂow in the respi-
ratory chain, stimulate ATP hydrolysis [10,12] and impair the gen-
eration and maintenance of the electrochemical membrane
potential [11]. In accordance with these results we found a reduced
ATP content in the presence of tamoxifen. Since ATP is indispens-
able for gluconeogenesis, it is reasonable to assume that its limita-
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initial linear portion of the curve. The initial slope obtained in the absence of
tamoxifen or 4-hydroxytamoxifen was subtracted.
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are numerous examples in the literature showing that inhibitors
of energy metabolism are able to affect gluconeogenesis in a neg-
ative way [35,36]. It must be added that the ratio of ATP to ADP
was also decreased by tamoxifen and that there are several studies
in which the regulatory inﬂuence of this ratio has been demon-
strated [37]. Furthermore, the conclusion that inhibition of energy
metabolism is a relevant mechanism is also corroborated by the
observation that the metabolite 4-hydroxytamoxifen is a more
effective gluconeogenesis inhibitor than the parent compound.
This is correct if one considers that 4-hydroxytamoxifen is also a
more effective inhibitor of energy metabolism than tamoxifen
[11]. It should be noted that the action of tamoxifen on oxygen
consumption by the liver is quite complex and it reﬂects, most
probably the complex interplay of several phenomena, some tend-
ing to increase and others to decrease oxygen consumption (Fig. 8).
This means that absence or near absence of alterations in oxygen
uptake do not mean absence of actions, because the situation
may arise in which a stimulatory action is compensated or nearlycompensated by an inhibitory action or vice versa. The phenomena
tending to increase oxygen uptake by the whole liver are uncou-
pling of the respiratory chain and stimulation of the microsomal
respiration due to biotransformation. That the latter occurs is indi-
cated by the observation that the compound stimulates oxygen up-
take in the presence of 1 mM cyanide, a condition for which the
mitochondrial respiratory chain is completely blocked [15] and
can no longer be stimulated by the classical uncoupler 2,4-dinitro-
phenol [38]. Inhibition of oxygen uptake, on the other hand, can be
promoted by a direct inhibitory action on the mitochondrial respi-
ratory chain [10,11], impairment of the cellular structure which
leads to enzyme losses, and competition with O2 at the binding site
of cytochrome c oxidase by NO, whose formation is stimulated by
tamoxifen [12]. Inhibition of the electron ﬂux in the respiratory
chain was indeed conﬁrmed in the present work by the measure-
ments of NADH-oxidase and succinate-oxidase of freeze–thawing
disrupted mitochondria. However, these oxidase activities in dis-
rupted mitochondria were much more sensitive to tamoxifen than
oxygen consumption in the intact liver. This observation is similar
to the observation of other investigators that found increased sen-
sitivity to tamoxifen of submitochondrial preparations when com-
pared to intact mitochondria [10,11].
Deviations of glucose 6-phosphate and malate from the main
route which leads to glucose output are likely to occur in the pres-
ence of tamoxifen (Fig. 8). It is well known that tamoxifen bio-
transformation includes several hydroxylation and demethylation
reactions which occur in the microsomal electron transport system
and which require NADPH as electron donor [39–41]. The main
sources of NADPH in the cytosol are the reactions catalyzed by
the malic enzyme and glucose 6-phosphate dehydrogenase [32].
As already mentioned above the existence of a cyanide insensitive
stimulation of oxygen consumption by tamoxifen in the rat liver
proves that the microsomal electron transport was active under
the conditions of our experiments. Although it seems of secondary
importance in the case of tamoxifen, for other gluconeogenesis
inhibitors, such as aminopyrine, it is of primary importance, be-
cause it is the only mechanism by which this compound inhibits
gluconeogenesis [32]. Conjugation of hydroxylated metabolites of
tamoxifen to glucuronic acid can also deviate glucose 6-phosphate
(see Fig. 8) with a diminution of glucose output. Normally the main
source of glucuronic acid is glycogenolysis [33], but in the virtual
absence of glycogen in livers from fasted rats [42], gluconeogenesis
is the sole possible source.
Although inhibition of energy metabolism and deviation of
intermediates of the gluconeogenic pathway seem to be reasonable
explanations for gluconeogenesis inhibition, it is unlikely that
these factors are the most important ones for the phenomenon at
the lowest tamoxifen concentrations. It should be recalled that
5 lM tamoxifen already inhibits lactate gluconeogenesis. Inhibi-
tion at low tamoxifen concentrations is characterized by its slow
onset, suggesting that it depends on events that also develop grad-
ually along the process of incorporation of the drug by the liver
cells, which occurs during infusion. Direct inhibition of key en-
zymes of the gluconeogenic pathway is unlikely to occur if one
takes into account the measurements conducted in the present
work. However, an action of tamoxifen on the short-term regula-
tion of these or other enzymes under cellular conditions should
not be ruled out. It has been recently shown by experiments with
isolated mitochondria that submicromolar concentrations of
tamoxifen stimulate the mitochondrial nitric oxide synthase activ-
ity by elevating the mitochondrial Ca2+ concentration [12,13]. In
addition to its contribution in hampering the mitochondrial respi-
ration, the elevated nitric oxide concentrations are likely to cause a
variety of effects. This includes gluconeogenesis (glucose output)
inhibition, which has been shown to occur in isolated hepatocytes
[34]. Inhibition was observed either with endogenously generated
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Fig. 5. Time courses of the changes in fructose gluconeogenesis, lactate production, pyruvate production and oxygen consumption caused by two different tamoxifen
concentrations. Livers from 24 h fasted rats were perfused as described under Materials and Methods. Fructose (5 mM) was infused at the indicated time as a gluconeogenic
substrate. Tamoxifen was infused at the indicated times at the concentrations of 25 lM (panel A) or 200 lM (panel B). Samples of the efﬂuent perfusate were collected for
metabolite assay. Oxygen in the outﬂowing perfusate was monitored polarographically. Data represent the means ± mean standard errors of three liver perfusion
experiments.
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ic pathway that is sensitive to nitric oxide is glyceraldehyde 3-
phosphate dehydrogenase [43], although a very precise correlation
between gluconeogenesis and the glyceraldehyde 3-phosphate
dehydrogenase activity could not be established [34].
Alterations in cell integrity can be another cause of events that
manifest themselves negatively on gluconeogenesis. It is important
to recall that tamoxifen strongly incorporates into biomembranes
[44] and interacts with lipids [5] and proteins [4,6]. The latter in-
cludes calmodulin, an important regulatory protein [4]. ConcerningTable 1
Inﬂuence of tamoxifen on the adenine nucleotide contents of perfuse
Henseleit-bicarbonate buffer containing 2 mM lactate in the absence (c
the livers with liquid nitrogen the adenine nucleotides were extracte
standard enzymatic procedures. The superscripts refer to the results of
Inﬂowing perfusate conditions ATP (lmol per gram liver wet
weight)
A
w
2 mM lactate (n = 4) 1.64 ± 0.03a 0
2 mM lactate + 200 lM
tamoxifen (n = 5)
0.98 ± 0.05a 0
a p < 0.001.
b p = 0.002.
c p = 0.006.the membrane dynamics, it has been recently shown that tamoxi-
fen decreases membrane ﬂuidity at low concentrations but that the
opposite occurs at high concentrations [8]. Tamoxifen induces
hemolysis of erythrocytes as a function of concentration [7]. The
tamoxifen-induced hemolysis has been proposed to result from a
structural perturbation of the red cell membrane, leading to
changes in the framework of the membrane and its cytoskeleton
because of its high local concentration [8]. That these kind of phe-
nomena also occur in the liver is suggested by the observation that
tamoxifen causes the release of both cytosolic and mitochondriald rat livers. Livers were perfused in an open system with Krebs-
ontrol) and presence of 200 lM tamoxifen. After freeze-clamping
d with cold perchloric acid. Determination was accomplished by
the Student’s t test given just below the table.
DP (lmol per gram liver wet
eight)
AMP (lmol per gram liver wet
weight)
.74 ± 0.05b 0.25 ± 0.02c
.94 ± 0.01b 0.14 ± 0.02c
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Fig. 7. Time courses of lactate dehydrogenase and fumarase release into the
outﬂowing perfusate elicited by the infusion of tamoxifen at different concentra-
tions. Livers from fed rats were perfused with substrate-free perfusion medium as
described under Materials and Methods. The time points at which tamoxifen
infusion was initiated as well as the corresponding concentrations are indicated.
Samples of the efﬂuent perfusion ﬂuid were collected for enzyme assay, as
described in the Materials and Methods section. Data ± mean standard errors are
from 3–5 liver perfusion experiments.
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trations with a complex kinetics, although it is faster and more in-
tense at high concentrations. The enzyme losses caused by
tamoxifen are certainly not restricted to lactate dehydrogenase
and fumarase, which must be regarded here merely as markers
for cytosolic and mitochondrial proteins. Actually, lactate dehydro-
genase release in addition to transaminase release have been ob-
served in rats with liver damage induced by tamoxifen [45].
Elevated serum transaminase levels have also been observed in pa-
tients under tamoxifen treatment [46]. Although enzyme losses are
likely to result in diminished metabolic activity, other structural
alterations may exert a pronounced inﬂuence as well, the overall
effect being a reduction in biosynthetic activity, which is well
known for its dependence on cell integrity [29].
Stimulation of glycolysis (lactate production) observed in the
present work is probably the consequence of a compensatory reg-
ulation due to the inhibition of energy metabolism. There are
numerous examples of inhibitors of the mitochondrial function
that stimulate glycolysis [35,36]. Consistently, tamoxifen stimu-
lated glycolysis from both endogenous glycogen and fructose. It
should be remarked, however, that at high tamoxifen concentra-
tions inhibition tended to develop during the long infusion periods
when fructose was the substrate. It is possible that the same would
happen with glycogen-driven glycolysis. The depletion of glycogen,
however, was an impeditive to long experiments with tamoxifen.
Two causes can be devised for this inhibition that develops slowlyat longer infusion times: (a) progressive glyceraldehyde 3-phos-
phate dehydrogenase inhibition by the tamoxifen induced nitric
oxide formation and (b) alterations in cell integrity, also promoted
by tamoxifen as discussed above. With reference to possibility (a)
it should be noted that the glyceraldehyde 3-phosphate dehydro-
genase catalyzes a reversible step that is common to both glycoly-
sis and gluconeogenesis.
An important question to be discussed is one about the physio-
logical signiﬁcance of the actions observed in the present work.
Toxicology of tamoxifen is certainly a major concern and there
have been many attempts of dose reduction without affecting its
activity in reducing breast cancer risk [47]. Liver toxicity, as often
revealed by increased transaminase and lactate dehydrogenase
levels, is generally believed to involve mitochondrial dysfunction
that causes steatosis due to modiﬁed beta-oxidation of fatty acids,
generation of reactive oxygen species and ATP depletion
[45,46,48]. Tamoxifen induced hepatotoxicity is especially fre-
quent in breast cancer patients with pre-existing liver steatosis
[46,48]. In general terms it can be said that the effects observed
in the present work are compatible which the reported hepatotoxic
actions of tamoxifen. The question if the concentrations at which
tamoxifen was active in the isolated perfused rat liver are compat-
ible with the actual concentrations reaching the liver in the living
Fig. 8. Schematic representation of the main actions of tamoxifen that lead to gluconeogenesis inhibition. Reactions and pathways are generally represented in abbreviated
form. The symbol means stimulation; inhibition. The arrows indicate the predominant metabolic ﬂux direction under the speciﬁc experimental conditions.
Abbreviations: FbisPase, fructose 1,6-bisphosphatase; GAPDH, glyceraldehyde 3-phosphate dehdyrogenase; G6PDH, glucose 6-phosphate dehydrogenase; G6Pase, glucose 6-
phosphatase; a-KG, a-ketoglutarate; MDH, malate dehydrogenase; NO, nitric oxide; PC, pyruvate carboxylase; PEPCK, phosphoenolpyruvate carboxykinase.
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knowledge of the concentration of tamoxifen in the portal vein
after oral administration of various doses. It has been shown for
several other drugs that the peak portal concentrations are gener-
ally much higher than the systemic concentration. The difference
may reach factors of 5 or more [49]. Data on this respect are, unfor-
tunately, not available for tamoxifen. Data are available, however,
on both the systemic and hepatic tissue concentrations of tamoxi-
fen and metabolites in rats, mice and humans. Studies reveal that
much higher doses of tamoxifen are required to produce toxic ef-
fects and similar systemic concentrations in rats than in humans.
The difference is very pronounced, as demonstrated by a classic
study on this topic [50]. In the rat, chronic administration of
200 mg/kg daily resulted in systemic tamoxifen, N-desmethyl-
tamoxifen and 4-hydroxytamoxifen of 3, 7 and 0.08 lM, respec-
tively [50]. In breast-cancer patients comparable concentrations
were reached with much lower daily doses, approximately 5 mg/
kg [50]. Obviously, the rat is much less sensitive to tamoxifen thanhumans and it also handles tamoxifen muchmore efﬁciently. Actu-
ally, in humans, even much lower doses can produce relatively
high systemic tamoxifen + metabolite concentrations, especially
in patients already presenting hepatic dysfunction [48]. In the he-
patic tissue the concentrations of tamoxifen and metabolites are
relatively high. For the rat, maximal tamoxifen, N-desmethyltam-
oxifen and 4-hydroxytamoxifen concentrations of 260, 250 and
33 lM have been reported [50]. Tissue contents in humans present
great variations, but values up to 20 and 50 lM have been reported
for tamoxifen and N-desmethyltamoxifen [51]. The presence of
tamoxifen metabolites in both circulation and tissues [41,51] is
an important phenomenon because these compounds can also be
active on liver metabolism, as indeed demonstrated for 4-hydroxy-
tamoxifen. It should be added that time is also an important factor
in the development of the effects, as seen in several experiments of
this work. The rates of gluconeogenesis inhibition shown in Fig. 4
can be used to calculate the approximate time required to reach
a given degree of inhibition for the various tamoxifen concentra-
32 C.B. Marek et al. / Chemico-Biological Interactions 193 (2011) 22–33tions. For example, 50% inhibition of lactate gluconeogenesis (from
0.65 to 0.325 lmol min1g1) will be reached in 2.9 and 1.6 h with
5 and 10 lM tamoxifen, respectively. Moreover, numerical inter-
polation with Stineman’s formula reveals that with 1 lM tamoxi-
fen 14.6 h will be required for 50% inhibition. This is a long time
for doing perfusion experiments, but a relatively short time if
one considers the long exposure (days, months) during intense or
chronic treatment. Taking all these points into account one can
really not exclude the possibility that the actions of tamoxifen de-
scribed in this study can be signiﬁcant for the liver at least during a
certain phase just after oral intake of the drug. The multiple actions
of tamoxifen can represent a continuous burden to the overall he-
patic functions during long treatment periods. Maintenance of glu-
cose homeostasis under the clearly unfavorable conditions induced
by tamoxifen, for example, may require regulatory adaptations
that are harmful to the cell’s functioning. In the long term, such a
situation is likely to contribute to uneasy conditions for the liver
functions and, in extreme cases, to organ failure.
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